Which class provides cardiovascular risk reduction in addition to lowering blood glucose?

Which class provides cardiovascular risk reduction in addition to lowering blood glucose?

• A. Biguanides
• B. SGLT2 inhibitors
• C. Alpha-glucosidase inhibitors
• D. GLP-1 receptor agonists

Answer: (B)

The main idea is that some diabetes medicines do more than lower blood sugar—they also reduce cardiovascular risk. SGLT2 inhibitors lower glucose by blocking glucose reabsorption in the kidney, but they also trigger diuresis and natriuresis, which lowers blood pressure and plasma volume, and they promote modest weight loss. They also protect the kidneys, reducing albuminuria and slowing kidney function decline. In large cardiovascular outcome trials, these drugs reduced major adverse cardiovascular events and hospitalizations for heart failure, benefits seen across patients with established cardiovascular disease and those at high risk. That robust evidence for cardiovascular risk reduction, in addition to glucose lowering, makes this class the best fit for the question. Other options don’t show as consistent or pronounced cardiovascular risk benefits across the class: metformin’s CV benefit is less uniform, alpha-glucosidase inhibitors lack meaningful CV risk reduction, and while some GLP-1 receptor agonists show CV benefits, the evidence isn’t as consistently strong across the entire class as with SGLT2 inhibitors.

The main idea is that some diabetes medicines do more than lower blood sugar—they also reduce cardiovascular risk. SGLT2 inhibitors lower glucose by blocking glucose reabsorption in the kidney, but they also trigger diuresis and natriuresis, which lowers blood pressure and plasma volume, and they promote modest weight loss. They also protect the kidneys, reducing albuminuria and slowing kidney function decline. In large cardiovascular outcome trials, these drugs reduced major adverse cardiovascular events and hospitalizations for heart failure, benefits seen across patients with established cardiovascular disease and those at high risk. That robust evidence for cardiovascular risk reduction, in addition to glucose lowering, makes this class the best fit for the question. Other options don’t show as consistent or pronounced cardiovascular risk benefits across the class: metformin’s CV benefit is less uniform, alpha-glucosidase inhibitors lack meaningful CV risk reduction, and while some GLP-1 receptor agonists show CV benefits, the evidence isn’t as consistently strong across the entire class as with SGLT2 inhibitors.